tiprankstipranks
Advertisement

IEFA - ETF AI Analysis

Compare

Top Page

IEFA

iShares Core MSCI EAFE ETF (IEFA)

Rating:65Neutral
Price Target:
IEFA, the iShares Core MSCI EAFE ETF, earns a solid overall rating largely because many of its biggest holdings—such as HSBC, Novartis, AstraZeneca, ASML, and Mitsubishi UFJ—show strong financial performance, positive earnings outlooks, and generally supportive technical trends. This strength is partly offset by risks in names like Roche, Shell, and BHP, where valuation concerns, overbought or weak short-term technical signals, and growth challenges introduce some volatility, and the fund’s meaningful exposure to financials and large global cyclicals adds sector-related risk.
Positive Factors
Strong Leading Holding
The largest position, ASML Holding, has shown very strong performance, giving the fund a solid boost from its top holding.
Broad International Diversification
The ETF spreads its investments across many developed countries like Japan, the UK, and Europe, helping reduce the impact of problems in any single market.
Low Expense Ratio
The fund charges a very low fee, which means more of the investment returns stay in investors’ pockets over time.
Negative Factors
Reliance on One Standout Stock
ASML’s strong performance is a key driver of returns, so any weakness in this single stock could noticeably affect the fund.
Mixed Results Among Top Holdings
While several major positions have performed well, at least one large holding like AstraZeneca has been weak, slightly dragging on overall results.
Limited U.S. Exposure
The ETF has only a small allocation to U.S. stocks, so investors who want more exposure to the U.S. market would need to pair it with other funds.

IEFA vs. SPDR S&P 500 ETF (SPY)

IEFA Summary

IEFA is an ETF that follows the MSCI EAFE Investable Market Index, giving you broad exposure to stocks from developed countries outside North America, such as Japan, the UK, and Europe. It holds hundreds of companies of all sizes, including well-known names like Nestlé and HSBC, so you get instant global diversification in one investment. Someone might invest in IEFA to spread their money across many international markets and seek long-term growth beyond the U.S. stock market. A key risk is that international stocks can go up and down with global economic and currency changes.
How much will it cost me?The iShares Core MSCI EAFE ETF (IEFA) has an expense ratio of 0.07%, which means you’ll pay $0.70 per year for every $1,000 invested. This is lower than average because it’s a passively managed fund that tracks an index, keeping costs down.
What would affect this ETF?The iShares Core MSCI EAFE ETF (IEFA) could benefit from positive trends in developed markets outside North America, such as economic recovery in Europe or technological advancements in its top holdings like ASML and SAP. However, challenges like rising interest rates, geopolitical tensions, or regulatory changes in key regions could negatively impact sectors like financials and industrials, which make up a significant portion of the ETF's exposure.

IEFA Top 10 Holdings

IEFA’s story is driven by a handful of global heavyweights outside the U.S. ASML and BHP have been rising strongly, giving the fund a powerful boost from semiconductors and commodities, while Siemens and Shell add steady industrial and energy tailwinds. On the defensive side, Nestlé has been more mixed, and AstraZeneca is clearly lagging, softening some of the fund’s momentum from health care and consumer staples. With major positions in Europe, Japan, and Australia, IEFA is a broad developed-markets play rather than a single-country or sector bet.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
ASML Holding NV2.53%$4.91B€570.84B134.75%
76
Outperform
HSBC Holdings1.35%$2.62B£262.38B61.44%
80
Outperform
Roche Holding AG1.19%$2.32B$353.86B39.16%
73
Outperform
Novartis AG1.07%$2.09BCHF226.51B22.32%
80
Outperform
Shell (UK)0.98%$1.89B£184.29B22.78%
73
Outperform
Nestlé SA0.96%$1.86BCHF202.23B3.37%
71
Outperform
Siemens0.95%$1.85B€220.94B21.03%
74
Outperform
AstraZeneca0.94%$1.83B$251.50B1.53%
80
Outperform
Mitsubishi UFJ Financial Group0.93%$1.81B¥40.90T49.62%
76
Outperform
BHP Group Ltd0.93%$1.80BAU$342.12B70.12%
68
Neutral

IEFA Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price
Price Trends
50DMA
98.33
Positive
100DMA
96.69
Positive
200DMA
93.31
Positive
Market Momentum
MACD
0.54
Positive
RSI
47.03
Neutral
STOCH
25.14
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IEFA, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 100.59, equal to the 50-day MA of 98.33, and equal to the 200-day MA of 93.31, indicating a neutral trend. The MACD of 0.54 indicates Positive momentum. The RSI at 47.03 is Neutral, neither overbought nor oversold. The STOCH value of 25.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IEFA.

IEFA Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$194.70B0.07%
65
Neutral
$79.73B0.32%
66
Neutral
$31.71B0.33%
67
Neutral
$12.27B0.20%
65
Neutral
$11.48B0.28%
67
Neutral
$11.28B0.24%
68
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IEFA
iShares Core MSCI EAFE ETF
99.34
17.56
21.47%
EFA
iShares MSCI EAFE ETF
EFV
iShares MSCI EAFE Value ETF
ESGD
iShares ESG Aware MSCI EAFE ETF
FENI
Fidelity Enhanced International ETF
JIRE
JPMorgan International Research Enhanced Equity ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement